Health economics, long-term safety and studies of the clinical usefulness of the product are essential parts of post-marketing studies (Phase IV studies). LINK has accumulated expertise in these often disregarded aspects of clinical development. Maintenance of the Marketing Authorisation includes regulatory updates as well as monitoring of drug safety (pharmacovigilance), which are also essential post-marketing activities. It is important that all these elements are taken seriously and addressed according to professional standards.